Allergic rhinitis

Scott-Brown's Otorhinolaryngology: Head and Neck Surgery

Volumn , Issue , 2008, Pages 1386-1407

  Scadding, Glenis ^a   Durham, Stephen ^b  

^a ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872321142     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (124)

1. Bousquet J, van Cauwenberge P, Khaltaev N. Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. Journal of Allergy and Clinical Immunology. 2001; 108: S147-334.
2. Aberg N, Hesselmar B, Aberg B, Eriksson B. Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren between 1979 and 1991. Clinical and Experimental Allergy. 1995; 25: 815-9.
3. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and allergic rhinitis co-morbidity. Journal of Allergy and Clinical Immunology. 2000; 106: S201-5.
4. Strachan D, Sibbald B, Weiland S, Ait-Khaled N, Anabwani G, Anderson HR et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatric Allergy and Immunology. 1997; 8: 161-76.
5. Wuthrich B, Schindler C, Leuenberger P, Ackermann Liebrich U. Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss Study on Air Pollution and Lung Diseases in Adults. International Archives of Allergy and Immunology. 1995; 106: 149-56.
6. Barnes K, Marsh D. The genetics and complexity of allergy and asthma. Immunology Today. 1998; 19: 325-32.
7. Bahna SL. Factors determining development of allergy in infants. Allergy Proceedings. 1992; 13: 21-5.
8. Huovinen E, Kaprio J, Laitinen LA, Koskenvuo M. Incidence and prevalence of asthma among adult Finnish men and women of the Finnish Twin Cohort from 1975 to 1990, and their relation to hay fever and chronic bronchitis. Chest. 1999; 115: 928-36.
9. Holgate ST. Asthma genetics-waiting to exhale? Nature Genetics. 1997; 15: 227-9.
10. Butland BK, Strachan DP, Lewis S, Bynner J, Butler N, Britton J. Investigation into the increase in hay fever and eczema at age 16 observed between the 1958 and 1970 British birth cohorts. British Medical Journal. 1997; 315: 717-21.
11. Fujieda S, Diaz-Sanchez D, Saxon A. Combined nasal challenge with diesel exhaust particles and allergen induces in vivo IgE isotype switching. American Journal of Respiratory Cell and Molecular Biology. 1998; 19: 507-12.
12. De Marco R, Poli A, Ferrari M, Accordini S, Giammanco G, Bugiani M et al. The impact of climate and traffic related NO2 on the prevalence of asthma and allergic rhinitis in Italy. Clinical and Experimental Allergy. 2002; 32: 1405-13.
13. Graham DE, Koren HS. Biomarkers of inflammation in ozone-exposed humans. Comparison of the nasal and bronchoalveolar lavage. American Review of Respiratory Disease. 1990; 142: 152-6.
14. Braun-Fahrlander C, Gassner M, Grize L, Neu U, Sennhauser FH, Varonier HS et al. Prevalence of hay fever and allergic sensitization in farmer's children and their peers living in the same rural community. SCARPOL team. Swiss Study on Childhood Allergy and Respiratory Symptoms with Respect to Air Pollution. Clinical and Experimental Allergy. 1999; 29: 28-34.
15. Sibbald B, Strachan D. Epidemiology of rhinitis. In: Busse W, Holgate S (eds). Asthma and rhinitis. London UK: Blackwell Scientific, 1995: 32-43.
16. Kramer U, Heinrich J, Wjst M, Wichmann HE. Age of entry to day nursery and allergy in later childhood. Lancet. 1999; 353: 450-4.
17. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A Polymorphism in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. American Journal of Respiratory Cell and Molecular Biology. 1999; 20: 976-83.
18. Juniper EF. Impact of upper respiratory allergic diseases on quality of life. Journal of Allergy and Clinical Immunology. 1998; 102: S386-91.
19. Ragab S, Scadding GK, Lund VJ, Saleh H. Treatment of chronic rhinosinusitis and its effects on asthma. European Respiratory Journal. 2006; 28: 68-74.
20. Schramm B, Ehlken B, Smala A, Quednau K, Berger K, Nowak D. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: a one year retrospective study. European Respiratory Journal. 2003; 21: 116-22.
21. McWilliam AS, Nelson DJ, Holt PG. The biology of airway dendritic cells. Immunology and Cell Biology. 1995; 73: 405-13.
22. de-Vries JE, Gauchat J-F, Aversa G, Punnonen J, Gascan H, Yssel H. Regulation of IgE synthesis by cytokines. Current Opinion in Immunology. 1992; 3: 851-8.
23. Durham SR, Gould HJ, Thienes CP, Jacobson MR, Masuyama K, Rak S et al. Expression of epsilon germ-line gene transcripts and mRNA for the epsilon heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. European Journal of Immunology. 1997; 27: 2899-906.
24. Lebel B, Bousquet J, Morel A, Chanal I, Godard P, Michel FB. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. Journal of Allergy and Clinical Immunology. 1988; 82: 869-77.
25. Creticos PS, Peters SP, Adkinson Jr. N, Naclerio RM, Hayes EC, Norman PS et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. New England Journal of Medicine. 1984; 310: 1626-30.
26. Castells M, Schwartz LB. Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic response. Journal of Allergy and Clinical Immunology. 1988; 82: 348-55.
27. Spokas EG, Rokach J, Wong PY. Leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids. Methods in Molecular Biology. 1999; 120: 213-47.
28. Beaven MA. Histamine: its role in physiological and pathological processes. Monographs in Allergy. 1978; 13: 1-113.
29. Bachert C. Histamine-a major role in allergy? Clinical and Experimental Allergy. 1998; 6: 15-9.
30. Corrado OJ, Gould CA, Kassab JY, Davies RJ. Nasal response of rhinitic and non-rhinitic subjects to histamine and methacholine: a comparative study. Thorax. 1986; 41: 863-8.
31. Gerth-van-Wijk R. Nasal hyperreactivity: its pathogenesis and clinical significance. Clinical and Experimental Allergy. 1991; 21: 661-7.
32. Niimi N, Noso N, Yamamoto S. The effect of histamine on cultured endothelial cells. A study of the mechanism of increased vascular permeability. European Journal of Pharmacology. 1992; 221: 325-31.
33. Baldwin AL, Thurston G. Changes in endothelial actin cytoskeleton in venules with time after histamine treatment. American Journal of Physiology. 1995; 269: H1528-37.
34. Wagenmann M, Baroody FM, Cheng C, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Bilateral increases in histamine after unilateral nasal allergen challenge. American Journal of Respiratory and Critical Care Medicine. 1997; 155: 426-31.
35. Novak I, Falus A. Molecular biology and role of histamine in physiological and pathological reactions. A review. Acta Biologica Hungarica. 1997; 48: 385-94.
36. Howarth PH. Mediators of nasal blockage in allergic rhinitis. Allergy. 1997; 52: 12-8.
37. Sampson AP. The leukotrienes: mediators of chronic inflammation in asthma. Clinical and Experimental Allergy. 1996; 26: 995-1004.
38. Barnes NC, Smith LJ. Biochemistry and physiology of the leukotrienes. Clinical Reviews in Allergy and Immunology. 1999; 17: 27-42.
39. Wenzel SE. Inflammation, leukotrienes and the pathogenesis of the late asthmatic response [editorial;comment]. Clinical and Experimental Allergy. 1999; 29: 1-3.
40. Shaw RJ, Fitzharris P, Cromwell O, Wardlow AJ, Kay AB. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis. Allergy. 1985; 40: 1-6.
41. Volovitz B, Osur SL, Bernstein JM, Ogra PL. Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. Journal of Allergy and Clinical Immunology. 1988; 82: 414-8.
42. Miadonna A, Tedeschi A, Leggieri E, Lorini M, Folco G, Sala A et al. Behaviour and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. American Review of Respiratory Disease. 1987; 136: 357-62.
43. Knani J, Campbell A, Enander I, Peterson CG, Michel FB, Bousquet J. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secrections of patients with chronic rhinitis. Journal of Allergy and Clinical Immunology. 1992; 90: 880-9.
44. Proud D. The kinin system in rhinitis and asthma. Clinical Reviews in Allergy and Immunology. 1998; 16: 351-64.
45. Proud D, Togias A, Naclerio RM, Crush SA, Norman PS, Lichtenstein LM. Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. Journal of Clinical Investigation. 1983; 72: 1678-85.
46. Baumgarten CR, Togias AG, Naclerio RM, Lichtenstein LM, Norman PS, Proud D. Influx of kininogens into nasal secretions after antigen challenge of allergic individuals. Journal of Clinical Investigation. 1985; 76: 191-7.
47. Turner P, Dear J, Scadding G, Foreman JC. Role of kinins in seasonal allergic rhinitis: icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen. Journal of Allergy and Clinical Immunology. 2001; 107: 105-13.
48. Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteriod. American Journal of Respiratory and Critical Care Medicine. 1995; 151: 1900-6.
49. Bradding P, Feather IH, Howarth PH, Mueller R, Roberts JA, Britten K et al. Interleukin 4 is localized to and released by human mast cells. Journal of Experimental Medicine. 1992; 176: 1381-6.
50. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. American Journal of Respiratory Cell and Molecular Biology. 1994; 10: 471-80.
51. Gordon JR, Burd PR, Galli SJ. Mast cells as a source of multifunctional cytokines. Immunology Today. 1990; 11: 458-64.
52. Bradding P, Mediwake R, Feather IH, Madden J, Church MK, Holgate ST et al. TNF alpha is localized to nasal mucosal mast cells and is released in acute allergic rhinits. Clinical and Experimental Allergy. 1995; 25: 406-15.
53. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. Journal of Clinical Investigation. 1997; 99: 1492-9.
54. Enerback L, Pipkorn U, Olofsson A. Intraepithelial migration of mucosal mast cells in hay fever: ultrastructural observations. International Archives of Allergy and Applied Immunology. 1986; 81: 289-97.
55. Bascom R, Pipkorn U, Lichtenstein LM, Naclerio RM. The influx of inflammatory cells into nasal washings during the late response to allergen challenge. Effect of systemic steroid pre-treatment. American Review of Respiratory Disease. 1988: 406-12.
56. Naclerio RM, Proud D, Togias AG, Adkinson Jr. N, Meyers DA, Kagey-Sobotka A et al. Inflammatory mediators in late antigen-induced rhinitis. New England Journal of Medicine. 1985; 313: 65-70.
57. Silberstein DS. Eosinophil function in health and disease. Critical reviews in Oncology/Hematology. 1995; 19: 47-77.
58. Capron M, Desreumaux P. Immunobiology of eosinophils in allergy and inflammation. Research in Immunology. 1997; 148: 29-33.
59. Szucs E, Ravandi S, Goossens A, Beel M, Clement PA. Eosinophilia in the ethmoid mucosa and its relationship to the severity of inflammation in chronic rhinosinusitis. American Journal of Rhinology. 2002; 16: 131-4.
60. Schleimer RP, Bochner BS. The role of adhesion molecules in allergic inflammation and their suitability as targets of antiallergic therapy. Clinical and Experimental Allergy. 1998; 3: 15-23.
61. Schroeder JT, Kagey-Sobotka A, Lichtenstein LM. The role of the basophil in allergic inflammation. Allergy. 1995; 50: 463-72.
62. Varney VA, Jacobson MR, Sudderick RM, Robinson DS, Irani AM, Schwartz LB et al. Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils. American Review of Respiratory Disease. 1992; 146: 170-6.
63. Varga EM, Jacobson MR, Till SJ, Masuyama K, O'Brien F, Rak S et al. Cellular infiltration and cytokine mRNA expression in perennial allergic rhinitis. Allergy. 1999; 54: 338-45.
64. Holm AF, Fokkens WJ, Godthelp T, Mulder PG, Vroom TM, Rijntjes E. Effect of 3 months; nasal steroid therapy on nasal T cells and Langerhans cells in patients suffering from allergic rhinitis. Allergy. 1995; 50: 204-9.
65. Cromwell O, Hamid Q, Corrigan CJ, Barkans J, Meng Q, Collins PD et al. Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1 beta and tumour necrosis factor-alpha. Immunology. 1992; 77: 330-7.
66. Canonica GW, Ciprandi G, Pesce GP, Buscaglia S, Paolieri F, Bagnasco M. ICAM-1 on epithelial cells in allergic subjects: a hallmark of allergic inflammation. International Archives of Allergy and Immunology. 1995; 107: 99-102.
67. Devalia JL, Bayram H, Abdelaziz MM, Sapsford RJ, Davies RJ. Differences between cytokine release from bronchial epithelial cells of asthmatic patients and non-asthmatic subjects: effect of exposure to diesel exhaust particles. International Archives of Allergy and Immunology. 1999; 118: 437-9.
68. Denburg JA. Bone marrow in atopy and asthma: hematopoietic mechanisms in allergic inflammation. Immunology Today. 1999; 20: 111-3.
69. Roche N, Chinet TC, Huchon GJ. Allergic and nonallergic interactions between house dust mite allergens and airway mucosa. European Respiratory Journal. 1997; 10: 719-26.
70. Scadding GK. Non-allergic rhinitis: diagnosis and management. Current Opinion in Allergy and Clinical Immunology. 2001; 1: 15-20.
71. Demoly P, Michel F, Bousquet J. In vivo methods for study of allergy. Skin tests, techniques and interpretation. In: Middleton E, Reed C, Ellis E, Adkinson N, Yunginger J, Busse W (eds). Allergy, principles and practice, 5th edn. St Louis: Mosby Co, 1998: 530-9.
72. Pepys J. Skin testing. British Journal of Hospital Medicine. 1975; 14: 412.
73. Powe DG, Huskisson RS, Carney AS, Jenkins D, Jones NS. Evidence for an inflammatory pathology in idiopathic rhinitis. Clinical and Experimental Allergy. 2001; 31: 864-72.
74. Deuschl H, Johansson SG. Specific IgE antibodies in nasal secretion from patients with allergic rhintis and with negative or weakly positive RAST on the serum. Clinical Allergy. 1977; 7: 195-202.
75. Crobach MJ, Kaptein AA, Kramps JA, Hermans J, Ridderikhoff J, Mulder JD. The Phadiatop test compared with RAST, with the CAP system; proposal for a third Phadiatop outcome: "inconclusive". Allergy. 1994; 49: 170-6.
76. Bousquet J, Chanez P, Chanal I, Michel FB. Comparison between RAST and Pharmacia CAP system: a new automated specific IgE assay. Journal of Allergy and Clinical Immunology. 1990; 85: 1039-43.
77. Malm L, Gerth-van-Wijk R, Bachert C. Guidelines for nasal provocations with aspects on nasal patency, airflow, and airflow resistance. Rhinology. 1999; 37: 133-5.
78. Gore C, Custovic A. Can we prevent allergy? Allergy. 2004; 59: 151-61.
79. Arshad SH, Matthews S, Gant C, Hide DW. Prevention of atopic disease in children. Lancet. 1992; 339: 1493-7.
80. Murray CS, Pipis SD, McArdle EC, Lowe LA, Custovic A, Woodcock A. Lung function at one month of age as a risk factor for infant respiratory symptoms in a high risk population. Thorax. 2002; 57: 388-92.
81. Woodcock A, Lowe LA, Murray CS, Simpson BM, Pipis SD, Kissen P et al. Early life environmental control: effect on symptoms, sensitization and lung function at age 3 years. American Journal of Respiratory and Critical Case Medicine. 2004; 170: 433-9.
82. Gotzsche PC, Hammarquist C. Burr MHouse dust mite control measures in the management of asthma: meta-analysis. British Medical Journal. 1998; 317: 1105-10.
83. Terreehorst I, Hak E, Oosting AJ, Tempels-Pavlica Z, de Monchy JG, Bruijnzeel-Koomen CA et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. New England Journal of Medicine. 2003; 349: 237-46.
84. Woodcock A, Forster L, Matthews E, Martin J, Letley L, Vickers M et al. A Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. New England Journal of Medicine. 2003; 349: 225-36.
85. Sheikh A, Hurwitz B, Sibbald B, Barnes G, Howe M, Durham S. House dust mite barrier bedding for childhood asthma: randomised placebo controlled trial in primary care. BMC Family Practice. 2002; 3: 12.
86. O'Meara TJ, Sercombe JK, Morgan G, Reddel HK, Xuan W, Tovey ER. The reduction of rhinitis symptoms by nasal filters during natural exposure to ragweed and grass pollen. Allergy. 2005; 60: 529-32.
87. Bousquet J, Campbell A, Michel F. Antiallergic activities of antihistamines. In: Church M, Rihoux J (eds). Therapeutic index of antihistamines. Lewinston, NY: Hogretfe and Huber Publishers, 1992: 57-95.
88. Horak F, Stubner UP, Ziegelmayer R, Ing D, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in patients with grass pollen-induced allergic rhinitis in an allergen-exposure unit. Journal of Allergy and Clinical Immunology. 2002; 109: 956-61.
89. Timmerman H. Factors involved in the incidence of central nervous system side effects of H1 blockers. In: Church M, Rihoux J (eds). Therapeutic index of antihistamines. Lewinston, NY: Hogrefe and Huber Publishers, 1992: 19-31.
90. Scadding GK. Clinical assessment of antihistamines in rhinitis. Clinical and Experimental Allergy. 1999; 29: 77-81.
91. Woosley RL, Sale M. QT interval: a measure of drug action. American Journal of Cardiology. 1993; 72: 36B-43B.
92. Leurs R, Church MK, Taglialatela M. H1 antihistamines: inverse agonism, anti-inflammatory actions and cardiac side effects. Clinical and Experimental Allergy. 2002; 32: 489-98.
93. Ciprandi G, Passalacqua G, Mincarini M, Ricca V, Canonica GW. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Annals of Allergy, Asthma and Immunology. 1997; 79: 507-11.
94. ETAC R study-group. Allergic factors associated with the development of asthma and the influence of cetrizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC R. Pediatric Allergy and Immunology. 1998; 9: 116-24.
95. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. British Medical Journal. 1998; 317: 1624-9.
96. Scadding GK. Safety of intranasal steroids. Editorial in current opinion in ENT. London: RSM publications, 2002.
97. Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. Journal of Allergy and Clinical Immunology. 2002; 109: 636-42.
98. Crystal-Peters J, Nelusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related emergency department visits. Journal of Allergy and Clinical Immunology. 2002; 109: 57-62.
99. Engstrom I, Oberger E, Blyckert A, Kraepelien S. Disodium cromoglycate in the treatment of seasonal allergic rhinoconjunctivitis in children. Annals of Allergy. 1971; 29: 505-9.
100. Scadding GK. Rhinitis medicamentosa. Clinical and Experimental Allergy. 1995; 25: 391-4.
101. Bradley JG. Non prescription drugs and hypertension. Which ones affect blood pressure? Postgraduate Medical Journal. 1991; 89: 195-7, 201-2.
102. Johnson DA, Hricik JG. The pharmacology of alpha-adrenergic decongestants. Pharmacotherapy. 1993; 13: 110S-5S; discussion 43S-6S.
103. Thomas SH, Clark KL, Allen R, Smith SE. A comparison of the cardiovascular effects of phenylpropanolamine and phenylephrine containing proprietary cold remedies. British Journal of Clinical Pharmacology. 1991; 32: 705-11.
104. Kaiser HB, Findlay SR, Georgitis JW, Grossman J, Ratner PH, Tinkelman DG et al. Long-term treatment of perennial rhinitis with ipratropium bromide nasal spray 0.06%. Journal of Allergy and Clinical Immunology. 1995; 95: 1128-32.
105. Dockhorn R, Aaronson D, Bronsky E, Chervinsky P, Cohen R, Ehtessabian R et al. Ipratropium bromide nasal spray 0.03% and beclomethasone nasal spray alone and in combination for the treatment of rhinorrhea in perennial rhinitis. Annals of Allergy, Asthma and Immunology. 1999; 82: 349-59.
106. Groth S, Dirksen H, Mygind N. The absence of systemic side-effects from high doses of ipratropium in the nose. European Journal of Respiratory Diseases. Supplement. 1983; 128: 490-3.
107. Brooks CD, Karl KJ, Francom SF. Oral methylprednisolone acetate (Medrol tablets) for seasonal rhinitis: examination of dose and symptom response. Journal of Clinical Pharmacology. 1993; 33: 816-22.
108. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. American Journal of Respiratory and Critical Care Medicine. 1995; 151: 1734-9.
109. Pullerts T, Praks L, Skoogh BE, Ani R, Lotvall J. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. American Journal of Respiratory and Critical Care Medicine. 1999; 159: 1814-8.
110. Meltzer E, Malmstrom K, Lu S, Brenner B, Wei L, Weinstein S et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: placebo-controlled clinical trial. Journal of Allergy and Clinical Immunology. 2000; 105: 917-22.
111. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Montelukast Fall investigator group. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a muticenter, randomised, double-blind, placebo-controlled trial performed in the fall. Annals of Allergy, Asthma and Immunology. 2002;88: 592-600.
112. Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clinical and Experimental Allergy. 2001; 31: 1385-91.
113. Taccariello M, Parikh PP, Darby Y, Scadding GK. Nasal douching in chronic rhinosinusitis: a randomized, singleblind study comparing alkaline nasal douche and sterile sea water. Rhinology. 1999; 37: 29-32.
114. Bousquet J, Lockey R, Malling HJ, Alverez-Cuesta E, Canonica GW, Chapman MD et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. Annals of Allergy, Asthma and Immunology. 1998; 81: 401-5.
115. White P, Smith H, Baker N, Davis W, Frew A. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clinical and Experimental Allergy. 1998; 28: 266-70.
116. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. Journal of Allergy and Clinical Immunology. 2001; 107: 87-93.
117. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. New England Journal of Medicine. 1999; 341: 468-75.
118. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). Journal of Allergy and Clinical Immunology. 2002; 109: 251-6.
119. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. Journal of Allergy and Clinical Immunology. 1997; 99: 450-3.
120. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. Journal of Immunology. 2004; 172: 3252-9.
121. Till SJ, Francis JN, Nouri-Aria KT, Durham SR. Mechanisms of allergen immunotherapy. Journal of Allergy and Clinical Immunology. 2004; 113: 1025-34.
122. Simpson A, Custovic A. Allergen avoidance in the primary prevention of asthma. Current Opinion in Allergy and Clinical Immunology. 2004; 4: 45-51.
123. Wilson AM. Are antihistamines useful in managing asthma? Current Opinion in Allergy and Clinical Immunology. 2002; 2: 53-9.
124. Global strategy for asthma management and prevention. WHO/ NHLBI workshop report: National Institutes of Health, National Heart, Lung and Blood Institute Publication Number 95-3659; 1995.